Inhibition of IVA-PLA2 reprogrammed the lipid metabolism of effector CD8+ T cells, prevented CD8+ T cell senescence in vitro, and enhanced antitumor immunity and immunotherapy efficacy (in mouse models of melanoma and breast cancer in vivo) (39). Here, CD8A is linked to breast carcinoma.